Compare Amphastar Pharmaceuticals Inc (AMPH) vs Upwork Inc (UPWK) Price & Performance

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

UPWK trades at $9.67, up 2.65% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported Q2 2026 revenue of $191.7 million, at the high end of guidance, and adjusted EBITDA of $64.1 million exceeding outlook, per MarketBeat on August 10, 2026. Valuation ratios appear reasonable with a P/E of 11.93 and P/S of 1.7, while profitability remains strong with a net income margin of 13.81% in 2025.

The outlook is mixed; analyst consensus is 52% buy with no sell ratings, but recent earnings misses and legal investigations pose risks. Revenue growth has slowed to 2.9% year-over-year in 2025, and net cash flow turned negative, indicating potential headwinds. Investors should weigh solid fundamentals against execution challenges and AI-driven market shifts.